{"id":"clostridium-difficile-vaccine","safety":{"commonSideEffects":[{"rate":null,"effect":"Injection site reactions (pain, erythema, swelling)"},{"rate":null,"effect":"Fever"},{"rate":null,"effect":"Myalgia"},{"rate":null,"effect":"Fatigue"}]},"_chembl":{"chemblId":"CHEMBL2108709","moleculeType":"Enzyme"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"The vaccine is designed to elicit protective immune responses against C. difficile, a bacterium that causes severe gastrointestinal infections, particularly in hospitalized and elderly patients. By targeting bacterial toxins (toxins A and B) and/or other immunogenic antigens, the vaccine aims to prevent colonization, reduce disease severity, or prevent recurrent infections in vaccinated individuals.","oneSentence":"This vaccine stimulates the immune system to produce antibodies and cellular immunity against Clostridium difficile toxins and bacterial antigens to prevent infection and disease.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-28T01:42:05.553Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Prevention of Clostridium difficile infection (CDI)"},{"name":"Prevention of recurrent Clostridium difficile infection"}]},"trialDetails":[{"nctId":"NCT07282665","phase":"PHASE3","title":"A Study to Learn About a Clostridioides Difficile Vaccine in People 65 Years of Age and Older","status":"RECRUITING","sponsor":"Pfizer","startDate":"2025-12-10","conditions":"Clostridioides Difficile Associated Disease","enrollment":32000},{"nctId":"NCT05805826","phase":"PHASE1, PHASE2","title":"To Understand the Safety and Effects of a C. Difficile Vaccine With New Adds-Ons That Will Be Given to Healthy Adults","status":"ACTIVE_NOT_RECRUITING","sponsor":"Pfizer","startDate":"2023-03-23","conditions":"Clostridoides Difficile Associated Disease","enrollment":936},{"nctId":"NCT05182775","phase":"NA","title":"A Clinical Research on the Use of Fecal Bacteria Transplantation for Treatment of IgA Nephropathy","status":"COMPLETED","sponsor":"Shanxi Provincial People's Hospital","startDate":"2022-01-01","conditions":"IgA Nephropathy","enrollment":15},{"nctId":"NCT04026009","phase":"PHASE1","title":"Safety and Immunogenicity Study of GSK's Clostridium Difficile Vaccine 2904545A When Administered in Healthy Adults Aged 18-45 Years and 50-70 Years","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2019-08-05","conditions":"Clostridium Infections","enrollment":140},{"nctId":"NCT03918629","phase":"PHASE3","title":"Clostridium Difficile Vaccine 2-Dose Versus 3-Dose Study","status":"COMPLETED","sponsor":"Pfizer","startDate":"2019-04-01","conditions":"Clostridium Difficile Associated Disease","enrollment":1994},{"nctId":"NCT03090191","phase":"PHASE3","title":"Clostridium Difficile Vaccine Efficacy Trial","status":"COMPLETED","sponsor":"Pfizer","startDate":"2017-03-29","conditions":"Clostridium Difficile Infection","enrollment":17535},{"nctId":"NCT03579459","phase":"PHASE3","title":"Evaluation Of Clostridium Difficile Vaccine Lot Consistency In Healthy Adults 65 To 85 Years Of Age","status":"COMPLETED","sponsor":"Pfizer","startDate":"2018-07-31","conditions":"Clostridium Difficile Associated Disease","enrollment":1317},{"nctId":"NCT01887912","phase":"PHASE3","title":"Study of a Candidate Clostridium Difficile Toxoid Vaccine in Subjects at Risk for C. Difficile Infection","status":"TERMINATED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2013-07-30","conditions":"Clostridium Difficile Infection","enrollment":9302},{"nctId":"NCT02561195","phase":"PHASE2","title":"A Study To Investigate Two 3-dose Schedules Of A Clostridium Difficile Vaccine In Healthy Adults Aged 65 to 85 Years","status":"COMPLETED","sponsor":"Pfizer","startDate":"2015-07-16","conditions":"Clostridium Difficile Associated Disease","enrollment":300},{"nctId":"NCT02052726","phase":"PHASE1","title":"A Study To Investigate A Clostridium Difficile Vaccine In Healthy Adults Aged 50 To 85 Years, Who Will Each Receive 3 Doses Of Vaccine.","status":"COMPLETED","sponsor":"Pfizer","startDate":"2014-01-22","conditions":"Clostridium Difficile","enrollment":184},{"nctId":"NCT01230957","phase":"PHASE2","title":"Study of Different Formulations of a Clostridium Difficile Toxoid Vaccine Given at Three Different Schedules in Adults","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2010-10","conditions":"Clostridium Difficile Infection, Diarrhea","enrollment":650},{"nctId":"NCT01896830","phase":"PHASE1, PHASE2","title":"Study of a Candidate Clostridium Difficile Toxoid Vaccine in Healthy Adult Subjects Aged 40 to 75 Years in Japan","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2013-07","conditions":"Clostridium Difficile Infection","enrollment":102},{"nctId":"NCT02725437","phase":"PHASE1","title":"Clostridium Difficile Vaccine Safety, Tolerability, and Immunogenicity Study in Japanese Adults","status":"COMPLETED","sponsor":"Pfizer","startDate":"2016-02","conditions":"Clostridium Difficile Associated Disease","enrollment":100},{"nctId":"NCT02991417","phase":"PHASE1","title":"Oral Vaccination Against Clostridium Difficile Infection","status":"TERMINATED","sponsor":"Simon M. Cutting","startDate":"2017-01","conditions":"Clostridium Difficile Infection","enrollment":3},{"nctId":"NCT02316470","phase":"PHASE2","title":"Dose-Confirmation, Immunogenicity and Safety Study of the Clostridium Difficile Vaccine Candidate VLA84 in Healthy Adults Aged 50 Years and Older. Phase II Study","status":"COMPLETED","sponsor":"Valneva Austria GmbH","startDate":"2014-12","conditions":"Clostridium Difficile","enrollment":500},{"nctId":"NCT02117570","phase":"PHASE2","title":"A Study To Investigate A Clostridium Difficile Vaccine In Healthy Adults Aged 50 to 85 Years, Who Will Each Receive 3 Doses Of Vaccine.","status":"COMPLETED","sponsor":"Pfizer","startDate":"2014-07","conditions":"Clostridium Difficile Associated Disease","enrollment":185},{"nctId":"NCT01296386","phase":"PHASE1","title":"An Open-label Study Assessing Safety, Immunogenicity and Dose Response of IC84","status":"COMPLETED","sponsor":"Valneva Austria GmbH","startDate":"2010-12","conditions":"Clostridium Difficile Infection","enrollment":82},{"nctId":"NCT01706367","phase":"PHASE1","title":"Evaluation of a 3-dose Vaccination Regimen With One of Three Ascending Dose Levels of Clostridium Difficile Vaccine With or Without Adjuvant in Healthy Adults Aged 50 to 85 Years","status":"COMPLETED","sponsor":"Pfizer","startDate":"2012-09","conditions":"Clostridium Difficile Associated Disease","enrollment":192},{"nctId":"NCT00772343","phase":"PHASE2","title":"Study of a Clostridium Difficile Toxoid Vaccine (ACAM-CDIFF™) in Subjects With Clostridium Difficile Infection","status":"COMPLETED","sponsor":"Sanofi Pasteur, a Sanofi Company","startDate":"2009-02","conditions":"Diarrhea, Clostridium Difficile Infection","enrollment":116},{"nctId":"NCT00127803","phase":"PHASE1","title":"Safety, Tolerability, and Immunogenicity Study of a Clostridium Difficile Toxoid Vaccine in Healthy Adult Volunteers","status":"COMPLETED","sponsor":"Sanofi","startDate":"2005-07","conditions":"Clostridium Infections","enrollment":50},{"nctId":"NCT00772954","phase":"PHASE1","title":"Phase I Randomized, Placebo-Controlled, Double-Blind, Dose Ranging Study, Safety, Tolerability and Immunogenicity","status":"TERMINATED","sponsor":"Sanofi","startDate":"2006-03","conditions":"Clostridium Difficile Infection, Clostridium Difficile Diarrhea","enrollment":36},{"nctId":"NCT00214461","phase":"PHASE1","title":"Safety, Tolerability, and Immunogenicity of a Clostridium Difficile Toxoid Vaccine in Healthy Elderly Volunteers","status":"COMPLETED","sponsor":"Sanofi","startDate":"2005-11","conditions":"Clostridium Infections","enrollment":48}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":18,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Clostridium difficile vaccine","genericName":"Clostridium difficile vaccine","companyName":"Sanofi","companyId":"sanofi","modality":"Biologic","firstApprovalDate":"","aiSummary":"This vaccine stimulates the immune system to produce antibodies and cellular immunity against Clostridium difficile toxins and bacterial antigens to prevent infection and disease. Used for Prevention of Clostridium difficile infection (CDI), Prevention of recurrent Clostridium difficile infection.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":2,"withResults":2},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}